BNP Paribas Financial Markets
ACRS icon

BNP Paribas Financial Markets’s Aclaris Therapeutics ACRS Stock Holding History

BNP Paribas Financial Markets’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$188K Buy
35,524
+14,079
+66% +$62.8K ﹤0.01% 4266
2026
Q1 		$80.4K Sell
21,445
-71
-0.3% -$240 ﹤0.01% 4477
2025
Q4 		$64.8K Sell
21,516
-5,151
-19% -$13K ﹤0.01% 4574
2025
Q3 		$50.7K Buy
26,667
+9,894
+59% +$17.2K ﹤0.01% 4600
2025
Q2 		$23.8K Buy
16,773
+9,294
+124% +$12.6K ﹤0.01% 4524
2025
Q1 		$11.4K Buy
7,479
+6,033
+417% +$12.9K ﹤0.01% 4688
2024
Q4 		$3.59K Sell
1,446
-1,822
-56% -$4.53K ﹤0.01% 4963
2024
Q3 		$3.76K Sell
3,268
-131
-4% -$161 ﹤0.01% 3855
2024
Q2 		$3.74K Sell
3,399
-237,702
-99% -$279K ﹤0.01% 3784
2024
Q1 		$299K Buy
241,101
+23,747
+11% +$28.3K ﹤0.01% 3113
2023
Q4 		$228K Buy
217,354
+140,744
+184% +$429K ﹤0.01% 3156
2023
Q3 		$525K Buy
76,610
+46,064
+151% +$394K ﹤0.01% 2703
2023
Q2 		$317K Sell
30,546
-6,395
-17% -$57.9K ﹤0.01% 2820
2023
Q1 		$299K Buy
36,941
+27,947
+311% +$355K ﹤0.01% 2984
2022
Q4 		$142K Sell
8,994
-12,080
-57% -$194K ﹤0.01% 3125
2022
Q3 		$332K Buy
21,074
+7,717
+58% +$122K ﹤0.01% 3245
2022
Q2 		$186K Buy
13,357
+8,931
+202% +$125K ﹤0.01% 3117
2022
Q1 		$76.3K Sell
4,426
-6,426
-59% -$87.7K ﹤0.01% 3442
2021
Q4 		$158K Buy
10,852
+1,823
+20% +$27.6K ﹤0.01% 3465
2021
Q3 		$163K Buy
9,029
+7,373
+445% +$118K ﹤0.01% 3122
2021
Q2 		$29.1K Buy
+1,656
New +$37.6K ﹤0.01% 3440
2020
Q3 		– Sell
-10,655
Closed -$17.3K – 4211
2020
Q2 		$17.3K Buy
10,655
+24
+0.2% +$32 ﹤0.01% 3465
2020
Q1 		$11.1K Buy
10,631
+2,906
+38% +$3.96K ﹤0.01% 4012
2019
Q4 		$14.6K Buy
7,725
+2,206
+40% +$3.66K ﹤0.01% 4076
2019
Q3 		$5.96K Buy
5,519
+1,525
+38% +$2.16K ﹤0.01% 4248
2019
Q2 		$8.75K Sell
3,994
-3,413
-46% -$18.6K ﹤0.01% 4128
2019
Q1 		$44.4K Buy
7,407
+7,398
+82,200% +$49K ﹤0.01% 3571
2018
Q4 		$67 Sell
9
-838
-99% -$8.64K ﹤0.01% 4224
2018
Q3 		$12.3K Hold
847
– – ﹤0.01% 3638
2018
Q2 		$16.9K Sell
847
-4,095
-83% -$75.7K ﹤0.01% 3562
2018
Q1 		$86.6K Buy
4,942
+49
+1% +$1.04K ﹤0.01% 3263
2017
Q4 		$121K Buy
4,893
+2,905
+146% +$70.7K ﹤0.01% 3204
2017
Q3 		$51.3K Sell
1,988
-74
-4% -$1.98K ﹤0.01% 3130
2017
Q2 		$55.9K Buy
2,062
+2,037
+8,148% +$55.4K ﹤0.01% 3133
2017
Q1 		$746 Sell
25
-655
-96% -$18.9K ﹤0.01% 3761
2016
Q4 		$18.5K Sell
680
-17
-2% -$433 ﹤0.01% 3217
2016
Q3 		$17.9K Buy
697
+350
+101% +$7.42K ﹤0.01% 2956
2016
Q2 		$6.41K Buy
+347
New +$6.88K ﹤0.01% 3140
2016
Q1 		– Sell
-1,038
Closed -$28K – 2663
2015
Q4 		$28K Buy
+1,038
New +$20.2K ﹤0.01% 3157

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BNP Paribas Financial Markets's ACRS Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Aclaris Therapeutics (ACRS) stake by 66% in Q2 2026, buying an estimated $62.8K and bringing the position to 35,524 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #4266.

BNP Paribas Financial Markets first reported a position in ACRS in Q4 2015 and has held it in 39 quarters since. The position peaked at $525K in Q3 2023. 138 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • BNP Paribas Financial Markets held 35,524 shares of Aclaris Therapeutics worth $188K as of Q2 2026.
  • BNP Paribas Financial Markets bought 14,079 Aclaris Therapeutics shares in Q2 2026, an estimated $62.8K.
  • Aclaris Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4266 holding.
  • BNP Paribas Financial Markets first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 39 quarters since.
  • BNP Paribas Financial Markets's Aclaris Therapeutics position peaked at $525K in Q3 2023.
  • 138 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.